Physician profile
Gregory Davis
NPI 1497752877
$1,516.52
in general payments reported to CMS, 2019-2025
22 companies · $58.84 in 2025
The $58.84 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $264 · 2021: $439 · 2022: $108 · 2023: $29.94 · 2024: $172 · 2025: $58.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.61 | 2019-2022 | |
| Pfizer INC. | $184.69 | 2019-2024 | |
| Bausch Health US, LLC | $125.14 | 2020-2021 | |
| Astellas Pharma US INC | $113.64 | 2024 | Veozah |
| Amgen INC. | $91.41 | 2019-2022 | |
| Daiichi Sankyo INC. | $81.64 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $65.87 | 2019 | |
| Hologic Sales and Service, LLC | $52.89 | 2019-2022 | |
| Novo Nordisk INC | $48.74 | 2019-2020 | |
| Stryker Corporation | $45.07 | 2019 | |
| Olympus America INC. | $44.44 | 2019-2020 | |
| Boston Scientific Corporation | $42.10 | 2025 | General - Pain Management |
| Ethicon US, LLC | $34.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.51 | 2022-2025 | |
| Smith+Nephew, INC. | $30.99 | 2024 | Pico |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.89 | 2019 | |
| Therapeuticsmd, INC. | $20.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.06 | 2021 | |
| Ibsa Pharma INC. | $17.82 | 2020 | |
| Rochester Medical Corporation | $17.12 | 2019 | |
| Glaxosmithkline, LLC. | $14.29 | 2019 | |
| Ascend Therapeutics US, LLC | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.